On March 30, 2022, "Rendu Bio," an investee company of Qiming Venture Partners—a sub-fund backed by the mother fund managed by Yuanhe Chenchun Capital—officially listed on the STAR Market of the Shanghai Stock Exchange, with stock code: 688193. This makes Rendu Bio the first domestic publicly traded company whose primary business revolves around RNA-based molecular diagnostic products.

Founded in 2007, Rendu Biotech is dedicated to developing and promoting RNA molecular diagnostic products based on real-time fluorescence isothermal amplification technology (commonly known as SAT technology). It is one of the earliest life science companies in China focused exclusively on RNA isothermal amplification technologies and related products.

Rendu Biotech possesses a comprehensive suite of core technologies with independent intellectual property rights, covering everything from diagnostic reagents to the research, development, and production of fully automated, compatible instruments. Currently, the company has successfully established the SAT technology platform, securing 42 authorized patents and receiving NMPA registration certificates for 20 products that are now available on the market. Compared to DNA-based molecular diagnostic technology (PCR), SAT technology boasts superior features such as high sensitivity, strong specificity, minimal cross-contamination, and the ability to easily enable fully automated, high-throughput testing. Molecular diagnostic products built on SAT technology can be widely applied across various fields, including clinical diagnostics, blood screening, food safety testing, emergency prevention and control of infectious diseases, and rapid response initiatives.

As of March 25, 2022, Rendu Biotech held a total of 23 medical device products that have either been approved by the National Medical Products Administration (NMPA) or registered with the drug regulatory authorities. Among these, 13 are Class III medical devices (including 12 reagent products and 1 instrument product), while 10 are Class I medical devices that have been filed for registration.

This issuance by Rendu Biotech is expected to raise a total of RMB 726.50 million, which, after deducting issuance expenses, will be primarily allocated to the industrialization and R&D projects for precision diagnostic reagents and smart devices, as well as the construction of its marketing network. Moving forward, Rendu Biotech will continue leveraging its proprietary SAT technology platform to develop a range of innovative products, further addressing the evolving needs of clinicians and patients alike.